Ciprofloxacin or Tamsulosin in Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

  1. Richard B. Alexander, MD;
  2. Kathleen J. Propert, ScD;
  3. Anthony J. Schaeffer, MD;
  4. J. Richard Landis, PhD;
  5. J. Curtis Nickel, MD;
  6. Michael P. O'Leary, MD;
  7. Michel A. Pontari, MD;
  8. Mary McNaughton-Collins, MD, MPH;
  9. Daniel A. Shoskes, MD;
  10. Craig V. Comiter, MD;
  11. Nand S. Datta, MD;
  12. Jackson E. Fowler, Jr, MD;
  13. Robert B. Nadler, MD;
  14. Scott I. Zeitlin, MD;
  15. Jill S. Knauss, MS;
  16. Yanlin Wang, MS;
  17. John W. Kusek, PhD;
  18. Leroy M. Nyberg, Jr, MD, PhD;
  19. Mark S. Litwin, MD, MPH; and
  20. and the Chronic Prostatitis Collaborative Research Network*
  1. From Veterans Affairs Maryland Health Care System and University of Maryland School of Medicine, Baltimore, Maryland; University of Pennsylvania and Temple University, Philadelphia, Pennsylvania; Northwestern University, Chicago, Illinois; Queen's University, Kingston, Ontario, Canada; Brigham and Women's Hospital and Massachusetts General Hospital, Boston, Massachusetts; Cleveland Clinic Florida, Weston, Florida; University of Arizona, Tucson, Arizona; Charles Drew University and University of California, Los Angeles, California; University of Mississippi, Jackson, Mississippi; and the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
    1. Figure 1. The number of patients to whom the study was presented and discussed was not captured.
      View larger version:
      Figure 1. The number of patients to whom the study was presented and discussed was not captured. Flow of patients through the study, according to individual treatment group.
    2. Figure 2. All available data on all patients are included in the means; the sample sizes at each time point are as shown.
      View larger version:
      Figure 2. All available data on all patients are included in the means; the sample sizes at each time point are as shown. Mean values of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score (potential of 43 points) over time for the 4 individual treatment groups.

    Summary for Patients

    « Previous | Next Article »Table of Contents